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Monday, February 17, 2014 367afluorophore and the transition metal ion acceptor at different positions of
glutamate transporter EAAT3, we will be able to measure intrasubunit dis-
tance changes during Naþ, glutamate binding and transport.
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The recently solved 3D crystal structures reveal that the Naþ-coupled meli-
biose permease of Salmonella typhimurium (MelBSt) is a member of the Ma-
jor Facilitator Superfamily (MFS). These inside-closed conformations show
that Arg residues at positions 295 (Helix IX), 141 (Helix V), and 363
(Loop10-11) govern three clusters of electrostatic interactions for stabilizing
the sealed internal cavity between N- and C-terminal domains at the cyto-
plasmic side. The cluster of these electrostatic interactions is designated as
ionic lock. Except Lys at position 141 or 363, the replacement of R295,
R141, or R363 individually with Cys, Gln, Glu, Leu, or Lys shows inhibition
of active transport of melibiose to a level of 2 - 25 % of the WT, with little
effect on the binding affinities for both sugar and Naþ. Interestingly, a sup-
pressor D35E mutation at the periplasmic end of helix I was spontaneously
isolated from the R363Q mutant. Remarkably, introduction of D35E mutation
with each conformation-compromised mutant of R295, R141 (except R141E),
or R363 significantly rescues the melibiose transport to a level up to 90 % of
the WT. However, D35E mutation fails to restore the activity if two lock sites
are mutated by Cys simultaneously at any combination. Previous threading
model of MelBSt at inside-open conformation show that all the three lock sites
are at unlocked state. We conclude that these ionic locks are cooperative and
involved in the transport-required global conformational changes by an alter-
ation of locking and unlocking processes. Strikingly, these ionic locks are
conserved in MFS permeases. Furthermore, they link with human diseases;
e.g., some patients with GLUT1 Deficiency Syndrome are due to a single
mutation of Arg at predicted ionic locks of the glucose transporter GLUT1 ex-
pressed in the blood-brain barrier.
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Designed ankyrin repeat proteins have been shown to be useful for different
applications such as structural, mechanistic, clinical studies, as well as drug
development. We have constructed a combinatorial DNA library encoding
ankyrin repeat proteins by PCR-based assembly. The ankyrin proteins have
both N- and C-terminal caps and five internal repeats (called N5C). The esti-
mated diversity of the library is higher than 1020. Applying circular dichro-
ism spectroscopy, four purified proteins exhibit high melting temperature
(> 95 C). We have tested the constructed library for the selection of specific
ankyrin proteins targeting the melibiose transport in Escherichia coli. The
melibiose permease is one of few overexpressed proteins during bacterial
infection for gaining energy. Using cells with plasmid-encoded constructed
library and chromosomally-encoded MelA, the alpha-galactosidase, and
MelB, the melibiose permease, we have collected a group of N5C candidates
that alter the melibiose fermentation with no inhibition of glucose fermenta-
tion, indicating no effect on the downstream utilization pathways. Three can-
didates show significant inhibition of melibiose transport. Further tests, using
sugar transport assay on different genetic backgrounds, MelA activity assay,
and protein-protein interaction assay, have been applied to identify specific
effect. These preliminary studies suggested that one N5C protein possibly in-
hibits mel operon. These bio-reagents could be potentially applied to study
the sugar transport during bacterial infection and also facilitate transporter
proteins crystallography.
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Characterizing the proton binding site and its coupling to the substrate trans-
port??in XylE?
The diffusion of glucose across the plasma membrane is facilitated by carrier
proteins called GLUTs. In the absence of a crystal structure for GLUTs, XylE
serves as an excellent model to study the transport cycle in these proteins, not
only due to its high sequence and structural similarity, but since it is the onlyMFS member with structures in various conformational states. In this study,
we aim to characterize the structural determinants of substrate and proton
binding and their coupling to protein conformational transitions in XylE. Us-
ing multiple sets of equilibrium MD simulations and free energy perturbation
(FEP) calculations, we propose one of the acidic residues of XylE within the
transmembrane region of the protein as the uncharacterized proton-binding
site. Through comparative simulation studies, we show that the protonation
of this residue results in the breakage of a salt bridge, which in turn induces
the transition of the protein from the occluded state towards the open state.
The observed conformational coupling, which was reproduced in multiple in-
dependent simulations, appears to involve the rotation of TM2 and TM7, and
thereby perturbing the Xylose binding site as evident by the movement of
Y298. Using sequence analysis of GLUTs we show the absence of this mech-
anistically important salt bridge in GLUTs, which can account for their Hþ-
independent transport mechanism. This work hence claims to give insight
into the thermodynamic cycle corresponding to the change from outward fac-
ing occluded state to the open state and hence helps in elucidating the entire
cycle in future.
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Current mechanistic models of the bacterial outer membrane TonB-dependent
transporters (TBDT) suggest that transport is driven by the proton motive force
(pmf) via interactions with the cytoplasmic membrane proteins TonB/ExbB/
ExbD. Studies of these systems are challenging because of the lack of an in
vitro reconstituted system, and transport must be studied in whole cells, which
greatly limits biochemical and spectroscopic approaches. Use of evolved
tRNA-tRNA synthetase pairs (Young et al.) along with orthogonal chemistry
for specific placement of labels at non-sense mutations allows incorporation
of labels in vivo. To enhance the specificity of the labeling, we developed
the use of E. coli minicells that lack the chromosome but contain multi-copy
plasmids. Only plasmid-encoded proteins are produced in minicells after
separation from the mother cell and higher specificity of labeling is achieved.
Moreover, minicells have the native arrangement and components of both
membranes and periplasm, and physiological measurements can be made
such as pmf-dependent uptake of vitamin B12 through the TBDT BtuB.
To study properties of the outermembrane transporter in the absence of the inner
membrane, naturally occurring outer membrane vesicles (OMVs) (Schwech-
heimer et al.) are amenable for transport and spectroscopic studies. Both sides
of the OMV membrane are accessible to labels and spectroscopic probes are
incorporated into cysteines in over-expressed outer membrane proteins with
high specificity. This work is supported by NIH/NIGMS grant U54 GM087519.
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The AcrA/AcrB/TolC multidrug efflux pump confers Escherichia coli with
antibiotic resistance by sequestering toxic compounds foundwithin the periplasm
and inner membrane and extruding them into the extracellular space. The AcrB
trimer is the central component of this efflux complex. Anchored in the inner
membrane, it forms an asymmetric assembly that undergoes a conformational
cycle in which each protomer adopts three different structures (L, T andO states).
Importantly, the conformational cycle within AcrB is driven by the transloca-
tion of protons down the electrochemical gradient sustained by the inner mem-
brane, through a mechanism that has not been characterized so far. Here, we
investigate this microscopic mechanism through structural modeling, electro-
static calculations and molecular dynamics simulations based upon novel
high-resolution structural data.
Our results show how reversible protonation of key sites within the transmem-
brane domain translate into structural changes that are transduced to the periplas-
mic domain, thus coupling proton and drug transport. These conformational
changes can be understood in terms of semirigid roto-translations of two
368a Monday, February 17, 2014topologically equivalent 5-helix repeats. Importantly, we show that these
changes result in the opening and closing of water-filled pathways that reach
from either side of the membrane into the proton binding site, which is found
at the interface between repeats, half-way through the membrane. More specif-
ically, the transition between the L T, and O states of the functional cycle rep-
resents a change from inward to outward to inward-facing conformations.
Interestingly, our analysis also shows that the structural changes associated
with this alternating-access mechanism differ in the proton-free (L to T) and
proton-loaded (T to O) portions of the cycle, a feature that might be shared
by other ion-coupled secondary transporters. Finally, we propose a mechanism
of strict coupling between transmembrane and periplasmic domains, and thus
between proton-import and drug-efflux.
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Insertion and release of a solute into and from a vessel comprising biopoly-
mers is a fundamental function. A typical example is found in a multidrug
efflux transporter. ‘‘Multidrug efflux’’ signifies that solutes such as drug mol-
ecules with diverse properties can be handled. In earlier works, we showed
that the spatial distribution of the solute-vessel potential of mean force
(PMF) induced by the solvent plays imperative roles in the insertion/release
process. The PMF can be decomposed into the energetic and entropic com-
ponents. The entropic component, which originates from the translational
displacement of solvent molecules, is rather insensitive to the solute-
solvent and vessel inner surface-solvent affinities. This feature is not shared
with the energetic component. When the vessel inner surface is neither
solvophobic nor solvophilic, the solvents within the vessel cavity and in
the bulk offer almost the same environment to any solute, and the energetic
component becomes much smaller than the entropic component. Our idea is
that the multidrug efflux can be realized if the insertion/release process is
accomplished by the entropic component. However, we have recently argued
that the entropic release is not feasible as long as the vessel geometry is
fixed. Here we consider a model of TolC, a cylindrical vessel possessing
an entrance at one end and an exit at the other end for the solute. The spatial
distribution of the PMF is calculated by employing the three-dimensional in-
tegral equation theory with rigid-body models whose behavior is purely
entropic in origin. We show that the entropically inserted solute can be
released by a continuous variation of the vessel geometry which forms a
time-dependent entropic force continuing to accelerate the solute motion to
the exit. Solutes with a wide range of sizes are entropically released using
the same vessel-geometry variation.
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The bacterial phosphotransferase system (PTS) drives unidirectional transport
of saccharides across the inner cell membrane and signals the intracellular
availability of these sugars. Directionality of transport is accomplished through
phosphorylation of the sugar by the soluble protein enzyme IIB (EIIB) while it
is bound to the component of the PTS responsible for translocation, the integral
membrane protein enzyme IIC (EIIC). The first crystal structure of an EIIC was
recently reported1. The N,N’-diaceylchitobiose transporter, a homolog of
E. coli ChbC, was crystallized in a state in which the bound substrate is not sol-
vent accessible from either side of the membrane. In order to further charac-
terize the EIIC conformational changes needed to translocate the sugar
molecule across the bilayer and covalently modify the sugar, we have taken
several approaches. We cloned and screened 91 ChbC homologs with the
goal of solving structures that assume different solvent accessbility to the
bound substrate. We found 11 homologs that are suitable for crystallization,7 of which contain an EIIB domain. Molecular dynamics simulations, as
well as mutational studies, were conducted to investigate motions of domains
that are responsible for substrate translocation and phosphorylation.
1 Cao, Y.; et al., Crystal Structure of a phosphorylation-coupled saccharide
transporter. Nature2011, 473 (7345), 50-54.
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Transporters utilize electrochemical gradients across membranes to translo-
cate their substrates through the membranes. Many eukaryotic plasma mem-
brane symporters transport substrates in a Naþ-dependent manner by using
an electrochemical Naþ gradient across plasma membranes, while exchangers
couple the movement of a substrate against its electrochemical gradient with
the movement of another substrate down its electrochemical gradient in the
opposite direction. Although the Naþ gradient is ubiquitous and stable, the
electrochemical gradients of substrates for exchangers usually depend on cells
and are affected by cellular conditions. The concentrations of intracellular
substrates limit the accumulation of extracellular substrates thorough ex-
changers. To overcome the constraint, exchangers need to couple with other
proteins that help accumulation of substrates around exchangers. We have
been proposing that such functional coupling of transporters is general and
constitutes the functional unit of transport that we call ‘‘transportsome’’.
Here, we show one of the examples. Proteomics analysis following
co-immunoprecipitation revealed that urate-anion exchanger URAT1 and
Naþ-dependent anion transporter SMCT2 formed a complex through scaffold
protein PDZK1 in the apical membrane of renal proximal tubules. FRET
experiment clearly indicated that PDZK1 assembled URAT1 and SMCT2 in
living cells. To elucidate functional coupling of the transporters, URAT1
and SMCT2 were overexpressed in insect cells, purified and reconstituted
into proteoliposomes in the presence or absence of PDZK1. The initial rate
of urate-uptake was increased in the presence of Naþ when co-reconstituted
with PDZK1 while Naþ did not alter the rate without PDZK1. These results
suggest that SMCT2 generate an electrochemical gradient of the substrate
which drives the urate-uptake via URAT1 located in close proximity to
SMCT2 with PDZK1 scaffold. Taken together, the transporters and the scaf-
fold protein formed Transportsome for urate-transport.
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Folate cofactors, Vitamin B9, play crucial roles in more than a hundred one-
carbon metabolism reactions in mammalian cells. Humans cannot synthesize
folates de novo and absorption through the diet is the only source of this
vitamin. The proton-coupled folate transporter (PCFT) mediates this uptake
in the upper small intestine by a pH-dependent process. PCFT also transports
folates into the central nervous system. Point mutations in the PCFT gene
cause Hereditary Folate Malabsorption (HFM), with associated hematological
and neurological defects due to impaired folate transport. Certain solid tumor
cell lines express high levels of PCFT mRNA. Importantly, the overall expres-
sion of PCFT is limited to only certain tissues in humans. Therefore, PCFT is
a molecular target for specific delivery of anti-folate chemotherapeutic agents
to tumor cells. Unfortunately, the success rate of anti-folate agents to reach
clinical use is very low due to their side-effects. A structural model of
PCFT can aid the development of specific anti-folate agents for their
PCFT-targeted delivery and thus minimize their side-effects. To optimize
and verify an initial structural model of PCFT, we applied a wide array of
experimental approaches: solvent accessibility profiling through substituted
cysteine accessibility scanning, studying the helix packing, and assaying the
functionality of PCFT mutants. We complemented the experimental data
with theoretical approaches for structure prediction such as homology
modeling/threading, ligand docking and an extensive review of other second-
ary transporters and folate transport proteins. With these combined ap-
proaches, we have developed a structural model of PCFT that accurately
reflects our experimental observations. This model forms a basis to understand
the impacts of HFM mutations, and to develop folate analogues for folate defi-
ciency intervention. Additionally, it will aid the design of PCFT structure-
based anti-folate agents for the treatment of cancer.
